Lumretuzumab

Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) . Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer[1][2].

Product Specifications

CAS Number

[1448327-63-6]

Product Name Alternative

Anti-Human ERBB3 Recombinant Antibody

UNSPSC

12352203

Target

Akt; EGFR; p38 MAPK; PI3K

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lumretuzumab.html

Purity

99.0

Solubility

H2O

Smiles

[Lumretuzumab]

Molecular Weight

(146.92 kDa)

References & Citations

[1]Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36 (5) :848-859.|[2]Collins D, et al. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS One. 2017 May 11;12 (5) :e0177331.